TrialPath

Find a study

Match me to a study

304 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

136 studies on the map

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — AMR Clinical, MobileA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) — AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, AvondaleA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — MD First Research - Chandler, ChandlerAMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Pinnacle Research Group LLC, AnnistonStudy of ALTO-300 in MDD — Site 200, PhoenixA Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Arizona Research Center, Inc., PhoenixA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight — Cullman Clinical Trials, CullmanA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Pinnacle Research Group, AnnistonAMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Neighborhood Healthcare, EscondidoEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Headlands Research, ScottsdaleA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Medical Dermatology Specialists, PhoenixA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — MFA Clinical Research, TuscaloosaAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Dignity Health, Mercy Gilbert, GilbertMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Neighborhood Healthcare, EscondidoAMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Univ of Alabama Birmingham, BirminghamConvergent Mechanisms Underlying Reprometabolic Syndrome in Women — University of Colorado School of Medicine, AuroraMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Valley Clinical Trials, NorthridgeA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Birmingham Clinical Research, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham Clinical Research, BirminghamEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — CenExel Anaheim Clinical Trials, AnaheimAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Artemis Insitute for Clin Res, San DiegoEfficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Kailera Clinical Site, AnnistonAMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — South Broward Research LLC, MiramarA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Lakeview Clinical Research, GuntersvilleA Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Arizona Clinical Trials-Chandler, ChandlerA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Cahaba Research, Inc., PelhamA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Uni of Alabama at Birmingham, BirminghamEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Kailera Clinical Site, CullmanA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, Tucson"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, HuntsvilleStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixEfficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Kailera Clinical Site, GlendaleZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder — Vanda Investigational Site, PhoenixA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, PheonixA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerEfficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity — Kailera Clinical Site, ChandlerFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamCaloric Restriction and Activity to Reduce Chemoresistance in B-ALL — Children's Hospital Los Angeles, Los AngelesStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreA Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) — University of Alabama, BirminghamA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use — Vanda Investigational Site, Los AngelesNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity — ClearVue Eye Care, RosevilleA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookTirzepatide in PWS, HO and GNSO — Children's Minnesota, Saint PaulOxytocin for Weight Loss in Adolescents — Massachusetts General Hospital, BostonModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimoreA Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity — Altasciences Clinical LA, Inc., CypressMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. — Monroe Biomedical Research, LouisvilleEfficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity — The Children's Hospital of Philadelphia, PhiladelphiaSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation — The University of Arizona College of Medicine- Phoenix, PhoenixSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV — University of Colorado - Anschutz Medical Campus, AuroraSocial Determinants and a Diabetes Prevention Program Tailored for African Americans — University Health, Kansas CitySemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinInvestigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism — Biomedical Research Imaging Center Marsico Hall (UNC), Chapel HillPhentermine's Impact on Treatment in Teens — University of New Mexico Health Sciences Center, AlbuquerquePramipexole to Enhance Social Connections — University of California, San Diego, San DiegoA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleAβ Dynamics in LLMD — NYU Langone Health, New YorkACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSupplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — Duke University (Asthma, Allergy and Airway Center), DurhamTirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity — Clinical and Translational Research Unit, Palo AltoWeight Loss Study: Genetics and Response to Naltrexone/Bupropion — Columbia University Medical Center, New YorkResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity — St. Jude Children's Research Hospital, MemphisA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) — Children's Hospital Los Angeles, Los AngelesStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity — Massachusetts General Hospital, BostonA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes — Altasciences Clinical Los Angeles, Inc., CypressFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaTirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors — Weill Cornell Medicine, New YorkPioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants — Texas Diabetes Institute/UH, San AntonioOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease — Cleveland Clinic Main Campus, ClevelandSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisA Mobile Intervention to Reduce Pain and Improve Health-III — Wake Forest University, Winston-SalemVaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Inova Health System, Falls ChurchSingle Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects — Cedars Sinai Medical Center, Los Angeles

Showing the 150 nearest — narrow your filters for fewer, closer studies.